Ibane Abasolo obtained degrees in Biochemistry and Biology from the University of Navarra in 1997 and 1998, respectively. During her doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), she studied the role of a peptide hormone, adrenomedullin, in the prostate cancer. Dr. Abasolo continued her postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where she focused on the study of key factors on the progression of pancreatic cancer and the development of the cerebellum. During this time, she gained extensive experience in experimental mouse models, including all steps from the generation of new transgenic models, to the molecular and cellular characterization of existing ones. Later, Dr. Abasolo moved to the High Technology Institute (PRBB, Barcelona), where she was trained in molecular imaging techniques such as microPET, SPECT and CT.

Dr. Abasolo has been part of the CIBER-BBN since 2007, when she joined the group led by Dr. Schwartz at the Vall d’Hebron Hospital, where she launched the Functional Validation and Preclinical Research Area (FVPR) of the CIBBIM -Nanomedicine as a technological platform from which industry or academic groups can advance in the preclinical development of its compounds. In fact, FVPR is part of Unit 20 and the Singular Scientific Technical Infrastructure (ICTS) Nanbiosis and is certified with ISO9001: 2015.

As a researcher, Dr. Abasolo currently collaborates in 4 European projects (NoCanTher, EvoNano, Safe-Med-Tech and Mimic-Key) and leads many other national projects, focused on improving the treatment of lysosomal storage disorders (PI18 / 00871 from ISCIII and ExoProd funded by FIPSE) or in the study of the role of tumor stem cells in cancer progression (NanoDireCT, RETOS-Collaboration project). At CIBER-BBN, Dr. Abasolo directly coordinates 3 intramural projects and a recently awarded valorization project (ADVERT).